KR20090023360A - Ｃ형 간염 바이러스 감염 바이오마커 - Google Patents

Ｃ형 간염 바이러스 감염 바이오마커 Download PDF

Info

Publication number
KR20090023360A
KR20090023360A KR1020087028981A KR20087028981A KR20090023360A KR 20090023360 A KR20090023360 A KR 20090023360A KR 1020087028981 A KR1020087028981 A KR 1020087028981A KR 20087028981 A KR20087028981 A KR 20087028981A KR 20090023360 A KR20090023360 A KR 20090023360A
Authority
KR
South Korea
Prior art keywords
subject
treatment
gene
genes
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087028981A
Other languages
English (en)
Korean (ko)
Inventor
라비 케이. 라마찬드란
매튜 더블유. 하딩
폴 알. 카론
마틴 씨. 보트필드
브라이언 제이 해어
라즈 반다루
케빈 엠 켈리허
캐서린 엔. 코넬
Original Assignee
버텍스 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 버텍스 파마슈티칼스 인코포레이티드 filed Critical 버텍스 파마슈티칼스 인코포레이티드
Publication of KR20090023360A publication Critical patent/KR20090023360A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2545/00—Reactions characterised by their quantitative nature
    • C12Q2545/10—Reactions characterised by their quantitative nature the purpose being quantitative analysis
    • C12Q2545/114—Reactions characterised by their quantitative nature the purpose being quantitative analysis involving a quantitation step

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087028981A 2006-04-26 2007-04-25 Ｃ형 간염 바이러스 감염 바이오마커 Ceased KR20090023360A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79552006P 2006-04-26 2006-04-26
US60/795,520 2006-04-26

Publications (1)

Publication Number Publication Date
KR20090023360A true KR20090023360A (ko) 2009-03-04

Family

ID=38656353

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087028981A Ceased KR20090023360A (ko) 2006-04-26 2007-04-25 Ｃ형 간염 바이러스 감염 바이오마커

Country Status (13)

Country Link
US (1) US20100028874A1 (enExample)
EP (1) EP2016195A4 (enExample)
JP (1) JP2009535036A (enExample)
KR (1) KR20090023360A (enExample)
CN (1) CN101479389A (enExample)
AU (1) AU2007244824A1 (enExample)
CA (1) CA2650616A1 (enExample)
IL (1) IL194920A0 (enExample)
MX (1) MX2008013796A (enExample)
NO (1) NO20084954L (enExample)
NZ (1) NZ573052A (enExample)
RU (1) RU2008146518A (enExample)
WO (1) WO2007127801A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190015294A (ko) * 2016-06-07 2019-02-13 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 세균성 감염 및 바이러스성 감염의 진단 방법
KR20210021768A (ko) * 2019-08-19 2021-03-02 주식회사 테라젠바이오 특정 약물의 타겟 유전자의 암종별 주요 기전 및 시그니처 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
JP2009178057A (ja) * 2008-01-29 2009-08-13 Miyazakiken Sangyo Shien Zaidan インターフェロンとリバビリンとの併用治療効果の検出方法および検出キット
AU2009296653A1 (en) * 2008-09-24 2010-04-01 Janssen Pharmaceutica Nv Therapeutic regimen comprising peg- interferon, ribavirin and VX-950 for the treatment of Hepatitis "
CN103119444B (zh) * 2010-04-21 2016-10-26 米密德诊断学有限公司 区分细菌与病毒感染的标记物和决定因素以及其使用方法
CN102178927A (zh) * 2011-03-01 2011-09-14 中国人民解放军军事医学科学院放射与辐射医学研究所 干扰素诱导跨膜蛋白3在制备抗乙型肝炎病毒感染药物中的用途
CN102323426A (zh) * 2011-08-08 2012-01-18 中国人民解放军军事医学科学院放射与辐射医学研究所 用于诊断或筛查丙型肝炎病毒感染的试剂
IN2014MN01780A (enExample) 2012-02-09 2015-07-03 Memed Diagnostics Ltd
CN106456677B (zh) * 2014-04-11 2025-06-03 全球免疫股份有限公司 基于酵母的免疫疗法和i型干扰素敏感性
CA2954601C (en) 2014-08-14 2023-04-18 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
WO2016026258A1 (en) * 2014-08-22 2016-02-25 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
US20170269081A1 (en) 2014-12-11 2017-09-21 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
WO2017149548A1 (en) 2016-03-03 2017-09-08 Memed Diagnostics Ltd. Rna determinants for distinguishing between bacterial and viral infections
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
WO2018011795A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11340223B2 (en) 2016-07-10 2022-05-24 Memed Diagnostics Ltd. Early diagnosis of infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
CN110073220A (zh) 2016-09-29 2019-07-30 米密德诊断学有限公司 风险评估和疾病分类的方法
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
CN108379584B (zh) * 2018-04-12 2020-08-11 上海交复生物医药科技有限公司 RSAD2通过wnt通路影响肿瘤细胞替莫唑胺耐药性
CN110448548B (zh) * 2018-05-08 2023-05-05 四川大学华西医院 Ifitm2抑制剂在制备治疗乙型肝炎的药物中的用途
CN111333710B (zh) * 2020-03-04 2021-12-03 暨南大学 C20orf24蛋白缺失突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006517960A (ja) * 2003-02-18 2006-08-03 ファイザー インコーポレイテッド Ｃ型肝炎ウイルスの阻害剤、それを使用する組成物および治療法
US20050282179A1 (en) * 2003-12-05 2005-12-22 Applera Corporation Biomarkers for interferon-alpha response in hepatitis C virus infected patients
AU2005321808B2 (en) * 2004-12-30 2009-08-20 University Of Louisville Research Foundation, Inc. Genetic markers of schizophrenia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190015294A (ko) * 2016-06-07 2019-02-13 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 세균성 감염 및 바이러스성 감염의 진단 방법
US11274345B2 (en) 2016-06-07 2022-03-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of bacterial and viral infections
KR20210021768A (ko) * 2019-08-19 2021-03-02 주식회사 테라젠바이오 특정 약물의 타겟 유전자의 암종별 주요 기전 및 시그니처 유전자들을 판단하는 전자 장치, 방법 및 상기 방법을 실행하기 위한 컴퓨터 프로그램

Also Published As

Publication number Publication date
NO20084954L (no) 2009-01-22
CN101479389A (zh) 2009-07-08
EP2016195A2 (en) 2009-01-21
WO2007127801A3 (en) 2008-09-12
US20100028874A1 (en) 2010-02-04
JP2009535036A (ja) 2009-10-01
RU2008146518A (ru) 2010-06-10
EP2016195A4 (en) 2010-03-10
AU2007244824A1 (en) 2007-11-08
CA2650616A1 (en) 2007-11-08
MX2008013796A (es) 2009-03-31
NZ573052A (en) 2012-03-30
WO2007127801A2 (en) 2007-11-08
IL194920A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
KR20090023360A (ko) Ｃ형 간염 바이러스 감염 바이오마커
Ziegler et al. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19
Banday et al. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries
Songok et al. Microarray analysis of HIV resistant female sex workers reveal a gene expression signature pattern reminiscent of a lowered immune activation state
Taylor et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy
JP5469744B2 (ja) インターフェロンアルファ応答に関連する遺伝子マーカー
Naggie et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B‐unfavorable genotype patients: Impaired viral kinetics and therapeutic response
Welzel et al. Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial
AU2009240021B2 (en) Antiviral therapy
US10072296B2 (en) Compositions and methods for sjögren's syndrome
JP2007529714A (ja) 遺伝子分析のための方法
Liao et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population
EP1953242A1 (en) Methods and kits for determining drug sensitivity in patientsinfected with HCV
WO2009034055A1 (en) Method for predicting the response of a subject suffering from a viral infection of the liver to an antiviral therapy
Resztak et al. Genetic control of the dynamic transcriptional response to immune stimuli and glucocorticoids at single-cell resolution
US20210079475A1 (en) Methods and kits for determining a personalized treatment regimen for a subject suffering from a pathologic disorder
Rauch et al. The recent breakthroughs in the understanding of host genomics in hepatitis C
Zhou et al. A Neanderthal OAS1 isoform protects against COVID-19 susceptibility and severity: results from Mendelian randomization and case-control studies
Banday et al. Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19
Carter et al. Pilot screening study of targeted genetic polymorphisms for association with seasonal influenza hospital admission
MacParland et al. Differential expression of interferon alpha inducible genes in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus and healthy donors
HK1130843A (en) Hepatitis c virus infection biomarkers
Katsounas et al. CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon‐α therapy and toll‐like receptor 3 signalling
Huang et al. Peripheral blood gene expression profile associated with sustained virologic response after peginterferon plus ribavirin therapy for chronic hepatitis-C genotype 1
Millian et al. Alterations in the hepatic microenvironment following direct-acting antiviral therapy for chronic hepatitis C

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120425

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131027

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140129

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131027

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I